Cover Image

Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]: corrigendum

Saved in:
Bibliographic Details
Main Authors: Radia, Deepti (Author) , Reiter, Andreas (Author)
Format: Article (Journal) Editorial
Language:English
Published: April 2022
In: Clinical lymphoma, myeloma & leukemia
Year: 2022, Volume: 22, Issue: 4, Pages: 276-276
ISSN:2152-2669
DOI:10.1016/j.clml.2021.12.002
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clml.2021.12.002
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S215226502102471X
Get full text
Author Notes:Deepti Radia, Daniel J. DeAngelo, Michael W. Deininger, Andreas Reiter, Jayita Sen, Hui-Min Lin, Sasa Dimitrijevic, Jason Gotlib

MARC

LEADER 00000caa a2200000 c 4500
001 1899157263
003 DE-627
005 20241205163826.0
007 cr uuu---uuuuu
008 240820s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clml.2021.12.002  |2 doi 
035 |a (DE-627)1899157263 
035 |a (DE-599)KXP1899157263 
035 |a (OCoLC)1475308063 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Radia, Deepti  |e VerfasserIn  |0 (DE-588)1339527375  |0 (DE-627)1899158022  |4 aut 
245 1 0 |a Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]  |b corrigendum  |c Deepti Radia, Daniel J. DeAngelo, Michael W. Deininger, Andreas Reiter, Jayita Sen, Hui-Min Lin, Sasa Dimitrijevic, Jason Gotlib 
264 1 |c April 2022 
300 |a 1 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 31. Januar 2022, Artikelversion: 29. März 2022 
500 |a Gesehen am 20.08.2024 
700 1 |a Reiter, Andreas  |d 1964-  |e VerfasserIn  |0 (DE-588)172629551  |0 (DE-627)697563766  |0 (DE-576)133488594  |4 aut 
773 0 8 |i Enthalten in  |t Clinical lymphoma, myeloma & leukemia  |d Amsterdam [u.a.] : Elsevier, 2010  |g 22(2022), 4 vom: Apr., Seite 276-276  |h Online-Ressource  |w (DE-627)620142014  |w (DE-600)2540998-0  |w (DE-576)358408776  |x 2152-2669  |7 nnas  |a Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368] corrigendum 
773 1 8 |g volume:22  |g year:2022  |g number:4  |g month:04  |g pages:276-276  |g extent:1  |a Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368] corrigendum 
787 0 8 |i Errata zu  |a Radia, Deepti  |t MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis  |d 2021  |w (DE-627)1900547430 
856 4 0 |u https://doi.org/10.1016/j.clml.2021.12.002  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S215226502102471X  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240820 
993 |a Editorial 
994 |a 2022 
998 |g 172629551  |a Reiter, Andreas  |m 172629551:Reiter, Andreas  |d 60000  |e 60000PR172629551  |k 0/60000/  |p 4 
999 |a KXP-PPN1899157263  |e 4569083706 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Deepti Radia, Daniel J. DeAngelo, Michael W. Deininger, Andreas Reiter, Jayita Sen, Hui-Min Lin, Sasa Dimitrijevic, Jason Gotlib"]},"note":["Online verfügbar: 31. Januar 2022, Artikelversion: 29. März 2022","Gesehen am 20.08.2024"],"recId":"1899157263","type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1899157263"],"doi":["10.1016/j.clml.2021.12.002"]},"language":["eng"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"April 2022"}],"person":[{"role":"aut","given":"Deepti","family":"Radia","display":"Radia, Deepti"},{"family":"Reiter","display":"Reiter, Andreas","given":"Andreas","role":"aut"}],"physDesc":[{"extent":"1 S."}],"title":[{"title":"Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]","subtitle":"corrigendum","title_sort":"Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Clinical lymphoma, myeloma & leukemia","title":"Clinical lymphoma, myeloma & leukemia"}],"titleAlt":[{"title":"Clinical lymphoma, myeloma and leukemia"}],"part":{"issue":"4","year":"2022","extent":"1","pages":"276-276","text":"22(2022), 4 vom: Apr., Seite 276-276","volume":"22"},"origin":[{"publisher":"Elsevier ; CIG Media Group","dateIssuedKey":"2010","dateIssuedDisp":"2010-","publisherPlace":"Amsterdam [u.a.] ; Dallas, Tex."}],"language":["eng"],"id":{"eki":["620142014"],"issn":["2152-2669"],"zdb":["2540998-0"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["10.2010 -"],"note":["Gesehen am 04.02.20"],"recId":"620142014","disp":"Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368] corrigendumClinical lymphoma, myeloma & leukemia"}]} 
SRT |a RADIADEEPTCORRIGENDU2022 

Similar Items